Health & Biotech
Race gets ethics nod for Phase I trial in solid tumour patients
The ASX players bringing new hope to IPF sufferers
Health Check: All hail the hard-working bodily ‘spuds’ – it’s World Kidney Day
Botanix climbs into ASX 300 club, strengthening its global dermatology ambitions
Health Kick Podcast: Imagion’s cancer imaging alternative
Health Check: Star biotech stocks are going cheap – or cheaper than they were
Biocurious: For Recce, our near neighbour was the obvious place to launch a diabetes-related trial
EZZ Life Science appoints US manufacturing partner
Audio health tech company Audeara amplifies reach with eyecare partnership
ReNerve scores marketing approval for nerve repair product in Thailand
Health Check: Poly oh no! Polynovo shares resume slide as CEO goes
Scott Power: ASX health sector falls as market faces gathering storm clouds
“Accelerate Action” to boost women’s leadership in Aussie healthcare sector
Health Check: More healthcare ‘reverse ferrets’ from Trump’s razor gang
Psilocybin can tackle brain injuries and binge eating, and these ASX companies are in the game
Compumedics secures FDA nod for second home sleep testing device
Race inks key contract to advance trial of cardioprotective anticancer treatment
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.
